HIMS falls after FDA GLP-1 drug warning overshadows Australia expansion
Hims & Hers Health shares began September in the red as an FDA warning about unapproved GLP-1 weight-loss drugs drew focus. The stock fell 4% to close at $28.44 on Tuesday.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.